UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1063-54 Long-term clopidogrel therapy is particularly beneficial for patients requiring repeat revascularization after an initial percutaneous coronary intervention

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A50-A50

2004

Volltextzugriff (PDF)

1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Annals of oncology, 2023-10, Vol.34, p.S660-S660

2023

Volltextzugriff (PDF)

1120P Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy

Annals of oncology, 2023-10, Vol.34, p.S674-S674

2023

Volltextzugriff (PDF)

12-P: Improved detection of HLA antibodies by LABScreen super(()R) single antigen using a Biotin-Streptavidin complex system

Human immunology, 2007-10, Vol.68 (1), p.S21-S21

2007

Volltextzugriff (PDF)

1328PContinental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

135 EXPRESSION OF APOPTOSIS-RELATED GENES IN BUFFALO (BUBALUS BUBALIS) EMBRYOS PRODUCED THROUGH IN VITRO FERTILIZATION AND PARTHENOGENETIC ACTIVATION

Reproduction fertility and development, 2011, Vol.23 (1), p.172

2011

Volltextzugriff (PDF)

A 160 kJ dual plasma focus (DuPF) for fusion-relevant materials testing and nano-materials fabrication

International Journal of Modern Physics: Conference Series, 2014, Vol.32, p.1460322

2014

Volltextzugriff (PDF)

16S rRNA gene Next-Generation Sequencing (16SNGS) for bacterial pathogen identification: Pilot Study in a malaysian teaching hospital

International journal of infectious diseases, 2020-12, Vol.101, p.184-184

2020

Volltextzugriff (PDF)

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Annals of oncology, 2019-10, Vol.30, p.v910

2019

Volltextzugriff (PDF)

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) plus nivolumab (NIVO) in stage III melanoma

ANNALS OF ONCOLOGY, 2019, Vol.30

2019

Volltextzugriff (PDF)

1905PAdvanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S145

2023

Volltextzugriff (PDF)

21. Recurrent hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival

Pathology, 2019-02, Vol.51, p.S154-S154

2019

Volltextzugriff (PDF)

296 Morphometric Assessment of Coronary Artery Stenoses Using Optical Coherence Tomography Compared to Fractional Flow Reserve In Patients With Stable Chest Pain Versus Acute Coronary Syndromes

Canadian journal of cardiology, 2012-09, Vol.28 (5), p.S204-S205

2012

Volltextzugriff (PDF)

33-OR: Cytotoxicity and antibody binding by flow cytometry: One assay to assess two parameters

Human immunology, 2007-10, Vol.68 (1), p.S117-S117

2007

Volltextzugriff (PDF)

3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate

European journal of cancer (1990), 2015-09, Vol.51, p.S666-S666

2015

Volltextzugriff (PDF)

36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

CANCER RESEARCH, 2020, Vol.80 (16)

2020

Volltextzugriff (PDF)

424Are current noninvasive investigation methods for LUTS useful in determining suitability for discharge following TURP?

European urology supplements : official journal of the European Association of Urology, 2005-03, Vol.4 (3), p.108-108

2005

Volltextzugriff (PDF)

5‐Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms

Journal of cutaneous pathology, 2017-03, Vol.44 (3), p.249-255

2017

Volltextzugriff (PDF)

6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

Immuno-oncology technology, 2022-12, Vol.16, p.100111, Article 100111

2022

Volltextzugriff (PDF)

72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone

Annals of oncology, 2024-09, Vol.35, p.S243-S243

2024

Volltextzugriff (PDF)

791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

Annals of oncology, 2022-09, Vol.33, p.S906

2022

Volltextzugriff (PDF)

798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis

Annals of oncology, 2022-09, Vol.33, p.S909

2022

Volltextzugriff (PDF)

A-204 Commitment to Sustainability From Laboratory Medicine

Clinical chemistry (Baltimore, Md.), 2024-10, Vol.70 (Supplement_1)

2024

Volltextzugriff (PDF)

1 – 25 von 934

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(831)
Mit Volltextzugriff
(798)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(933)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

1063-54 Long-term clopidogrel therapy is particularly beneficial for patients requiring repeat revascularization after an initial percutaneous coronary intervention

1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

1120P Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy

12-P: Improved detection of HLA antibodies by LABScreen super(()R) single antigen using a Biotin-Streptavidin complex system

1328PContinental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial

135 EXPRESSION OF APOPTOSIS-RELATED GENES IN BUFFALO (BUBALUS BUBALIS) EMBRYOS PRODUCED THROUGH IN VITRO FERTILIZATION AND PARTHENOGENETIC ACTIVATION

A 160 kJ dual plasma focus (DuPF) for fusion-relevant materials testing and nano-materials fabrication

16S rRNA gene Next-Generation Sequencing (16SNGS) for bacterial pathogen identification: Pilot Study in a malaysian teaching hospital

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) plus nivolumab (NIVO) in stage III melanoma

1905PAdvanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy

192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations

21. Recurrent hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival

296 Morphometric Assessment of Coronary Artery Stenoses Using Optical Coherence Tomography Compared to Fractional Flow Reserve In Patients With Stable Chest Pain Versus Acute Coronary Syndromes

33-OR: Cytotoxicity and antibody binding by flow cytometry: One assay to assess two parameters

3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate

36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

424Are current noninvasive investigation methods for LUTS useful in determining suitability for discharge following TURP?

5‐Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms

6P Response and survival according to the interferon-gamma (IFN-γ) signature and tumor mutational burden (tmb) in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma

72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone

791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma

797P Relapse-free survival (RFS) update and first translational analyses of DONIMI, a study testing personalized neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage III melanoma patients (pts) based on the interferon-gamma signature (IFN-γ sign) algorithm

798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis

A-204 Commitment to Sustainability From Laboratory Medicine

Suchergebnisse filtern